Showing results (81-90 of 89) with videos related to

Sort By:
Pageof 9
You have reached the last page of results.This site can display upto 89 results.
Blood|October 20, 2022
Venetoclax and idasanutlin in relapsed/refractory AML: a nonrandomized, open-label phase 1b trialNaval G Daver, Monique Dail, Jacqueline S Garcia, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 28, 2020
Venetoclax Plus Rituximab in Relapsed Chronic Lymphocytic Leukemia: 4-Year Results and Evaluation of Impact of Genomic Complexity and Gene Mutations From the MURANO Phase III StudyArnon P Kater, Jenny Qun Wu, Thomas Kipps, et al.
Blood Advances|June 27, 2020
Genetic and evolutionary patterns of treatment resistance in relapsed B-cell lymphomaChristopher K Rushton, Sarah E Arthur, Miguel Alcaide, et al.
Clinical Lymphoma, Myeloma & Leukemia|February 20, 2024
Venetoclax and Cobimetinib in Relapsed/Refractory AML: A Phase 1b TrialMarina Y Konopleva, Monique Dail, Naval G Daver, et al.
Journal of the National Cancer Institute|March 23, 2011
Multicenter independent assessment of outcomes in chronic myeloid leukemia patients treated with imatinibCarlo Gambacorti-Passerini, Laura Antolini, François-Xavier Mahon, et al.
The Oncologist|July 29, 2020
Checkpoint Blockade Treatment May Sensitize Hodgkin Lymphoma to Subsequent TherapyNicole A Carreau, Orrin Pail, Philippe Armand, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 10, 2015
Genetic Landscapes of Relapsed and Refractory Diffuse Large B-Cell LymphomasRyan D Morin, Sarit Assouline, Miguel Alcaide, et al.
The Oncologist|April 11, 2020
Impact of Treatment Beyond Progression with Immune Checkpoint Blockade in Hodgkin LymphomaReid W Merryman, Nicole A Carreau, Ranjana H Advani, et al.
American Journal of Hematology|February 26, 2020
Frontline treatment with the combination obinutuzumab ± chlorambucil for chronic lymphocytic leukemia outside clinical trials: Results of a multinational, multicenter study by ERIC and the Israeli CLL study groupYair Herishanu, Adir Shaulov, Riva Fineman, et al.
Pageof 9